Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 301–400 of 1,086
Reddy, Y. N. V., Frantz, R. P., Hassoun, P. M., Hemnes, A. R., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012912 · Cited by 8
Self-citationGries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
“Studies suggest an association between MASLD and HFpEF, but the exact relationship remains uncertain.”
InfluentialSattar, N., Weerakkody, G. J., McGuire, D. K., Kosiborod, M. N., Lee, M. M. Y., Welsh, P., Pearson, E. R., Wiese, R. J., Duffin, K., Wilson, J., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072889 · Cited by 6
Self-citationMetabolic dysregulation in the heart in obesity-associated HFpEF
Valero‐Muñoz, M., Cooper, H. L., Li, S. J., Saw, E. L., Wilson, R. M., Kusminski, C. M., Scherer, P. E., & Sam, F. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1678992 · Cited by 8
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension
Reddy, Y. N. V., Frantz, R. P., Miranda, W. R., Asokan, A. K., Varma, R., Rischard, F. P., Hassoun, P. M., Hemnes, A. R., Horn, E. M., Leopold, J. A., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.077606 · Cited by 7
Self-citationFarmakis, D. T., Karampinos, K. I., & Filippatos, G. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf730 · Cited by 6
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide
Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.04.044 · Cited by 5
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Bernardi, J. C., Cavalcante, D. V. S., Huntermann, R., Molinari, M. E., Zanon, L. Z., Khater, J., Gomez, V. A., & Fischer‐Bacca, C. O. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70192 · Cited by 5
“In such contexts, tirzepatide may be preferentially indicated for individuals with severe obesity, obesity-related organ dysfunction, or Type 2 diabetes requiring more rapid and intense metabolic improvement [24, 29].”
InfluentialPerivascular adipose tissue in cardiovascular disease: From mechanisms to therapeutic targets
Ueda, K. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.08.001 · Cited by 5
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Gaelzer, G. C., Prata, A. A., Rizzolli, L. G., Afonso, L., & Marques, G. L. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103194 · Cited by 5
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Thiriveedi, M., Domingo, F. S., Yates, H., Baddam, S., Beblawy, R. E., Nimmana, B., & Patel, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004055 · Cited by 7
“…SURMOUNT-4 [ 19 ] Phase 3, double-blind RCT 88 weeks (36-week tirzepatide lead in Obesity (maintenance study) 783 Sustained weight loss SUMMIT [ 20 ] Phase 3, double-blind RCT 52 weeks HFpEF + Obesity 1100 CV death or HF hospitalization Reference numbers in brackets correspond to the main…”
InfluentialEpicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?
Iacobellis, G. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02325-5 · Cited by 5
“These drugs provide weight loss and car - diovascular protective effects beyond diabetes control, as recently demonstrated [ 30 – 33].”
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Monzo, L., Savarese, G., Duarte, K., Baudry, G., Petrie, M. C., & Girerd, N. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag042 · Cited by 6
“4 However, the limited number of events in these studies precludes definitive conclusions.”
Xu, Y., Huang, T., Zhang, Y., Ji, D., Tuttle, K. R., Carrero, J. J., & Fu, E. L. (2026) · Circulation · doi:10.1161/circulationaha.125.075157 · Cited by 7
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
“In parallel, GLP-1 RA-based therapies are being tested in HFpEF management, with sema-glutide and tirzepatide demonstrating reductions in HF-related symptoms and improvements in health status among patients with HFpEF and obesity [106, 107].”
Lewsey, S. C., Martyn, T., Blumer, V. L., Brownell, N. K., Denfeld, Q. E., Dunlay, S. M., Goyal, P., Halloway, S., Matlock, D., Vardeny, O., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001437 · Cited by 7
Mechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction
Taqanaki, P. B., Aromolaran, K. A., & Aromolaran, A. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413423 · Cited by 7
“Targeting obesity as a therapeutic approach in HFpEF management has recently gained significant attention due to the success of the STEP-HFpEF [34]/STEP-HFpEF DM [35] and SUMMIT [36] trials in HFpEF patients with obesity receiving semaglutide and tirzepatide, respectively.”
InfluentialLahey, A. M., Duprey, K. S., Montague, R. C., Schadler, A. D., & Naseman, K. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70009 · Cited by 6
“25 Results from the SURPASS-CVOT study examining additional cardiovascular events with tirze-patide versus dulaglutide in patients with T2DM are anticipated to be published in the near future.”
Kim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
“…with Heart Failure with Preserved Ejection Fraction and Obesity) trial evaluated the efficacy and safety of once-weekly doses of tirze-patide on weight loss, HF symptoms, and clinical outcomes, including all-cause mortality and HF events, in patients with HFpEF with and without diabetes [106].”
Obesity and Comorbidities in HFpEF: A Retrospective Cohort Analysis in a University Hospital Setting
Hobbach, A. J., Brix, T. J., Weyer‐Elberich, V., Varghese, J., Reinecke, H., & Linke, W. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103348 · Cited by 5
“…peptide-1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists, may offer new therapeutic avenues for obese patients with HFpEF, especially women who are disproportionately affected and often represent a distinct clinical cluster population [26–28].”
Advances in Clinical Cardiology 2024: A Summary of Key Clinical Trials
Savage, P., Campbell, M., Hogg, M., McElhatton, D., & Menown, I. B. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03220-9 · Cited by 5
“…with significant symptom improvement (mean between-group KCCQ-CSS difference + 6.9; p < 0.001) and a reduction in the composite of CV death and HF hospitalisation (HR 0.62; p < 0.026) although low absolute numbers of events limit interpretation and further larger trials are required [79].”
InfluentialMaryam, M., Varghese, T. P., Tazneem, B., & Reddy, G. R. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00735-y · Cited by 5
Obesity in Cardiovascular Disease Prevention and Treatment---A Topic Getting “Heavier” as We Speak
Lavie, C. J., Hegele, R. A., Poirier, P., & Thompson, J. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.011 · Cited by 11
Ellberg, C. C., Schwartz, H. R., Witt, A., McCowen, K. C., Fuentes, A. L., & Malhotra, A. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00384-1 · Cited by 6
“…could tirzepatide be used to eliminate OSA in such patients? c) Although complex medical patients were excluded from SURMOUNT-OSA, should tirzepatide be used in patients with OSA plus DM or congestive heart failure [58], based on previously published studies in patients with these comorbidities?”
Defining HFpEF in rodents: a systematic review
Adrah, Y., Hegemann, N., Faidel, D., Kucherenko, M. M., Kuebler, W. M., Schiattarella, G. G., Beyhoff, N., & Grune, J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf174 · Cited by 7
Meyer, P., Rocca, A., Banús, J., Ogier, A. C. C., Georgantas, C., Calarnou, P., Fatima, A., Vallée, J., Deux, J., Thomas, A., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.043541 · Cited by 5
“23 However, substantial phenotype overlap limits the precision of such classifications.”
(2025) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000283 · Cited by 5
Hathorn, B., Haykowsky, M. J., Almandoz, J. P., Pandey, A., Sarma, S., Hearon, C. M., Babb, T. G., Balmain, B. N., Fu, Q., Zaha, V. G., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.015 · Cited by 9
Sotagliflozin: Two Birds with One Stone?
Requena-Ibáñez, J. A., Kindberg, K. M., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07723-z · Cited by 7
Foulkes, S., Ferreira, S. M., Milani, M., Bekhuis, Y., Falter, M., Delpire, B., Pauwels, R., Stroobants, S., Jogani, S., Vanhentenrijk, S., et al. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00587.2025 · Cited by 5
Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes
Hundal, J., Ashruf, O. S., Li, H., Basen‐Engquist, K., Kaelber, D. C., & Sukumar, J. S. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00844-6 · Cited by 6
Prevalence and Clinical Implications of Excess Adiposity in Group 1 Pulmonary Hypertension
Reddy, Y. N. V., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013591 · Cited by 6
Self-citationSex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials
van der Bijl, M. F., Scholte, N. T. B., van Oortmerssen, J. A. E., van Lennep, J. E. R., Schut, A., Westendorp, I. C. D., van der Boon, R. M. A., Brugts, J. J., Kardys, I., Appelman, Y., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag311 · Cited by 7
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
“Beyond T2D-specific CVOTs, tirzepatide has also been evaluated in obesity-related HFpEF through the placebo-controlled phase 3 SUMMIT trial, in which approximately half of participants also had T2D [14].”
InfluentialPharmacotherapy for obesity management
Noeth, M., Zyl, F. H. V., Hellig, J., Conradie-Smit, M., & May, W. (2025) · South African Medical Journal · doi:10.7196/samj.2025.v115i9b.3767 · Cited by 5
“[122] Treatment with tirzepatide (52 weeks) in patients with MASLD and moderate/severe fibrosis was more effective than placebo with regard to resolution of MASLD without worsening of fibrosis.”
Al-Ameri, L. T., Hameed, E. K., Dulaimi, Z., Abdalgbar, A., Wahdan, M. Y., Joboory, A. A., Mahmoud, S., Abdulla, M., Alshara, L., & Al-Dulaimi, N. F. (2024) · AL-Kindy College Medical Journal · doi:10.47723/hesy7z38 · Cited by 6
“It concludes that Tirzepatide lowers the risk of death from cardiovascular events or heart failure in patients with normal ejection fraction and Obesity (32-33).”
Weight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“31,32 While part of this benefit likely reflects weight loss, mediation analyses suggest that associated improvements in glycemia, blood pressure, and lipid profile account for only a fraction of the observed cardiovascular effect.”
Hellenkamp, K., Sato, R., & von Haehling, S. (2025) · Med · doi:10.1016/j.medj.2024.12.004 · Cited by 4
Agrawal, S. P., Tated, R. C. P., Maheta, D., & Aronow, W. S. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09656-9 · Cited by 5
Tirzepatide increased force of contraction in the isolated human atrium
Neumann, J., Hofmann, B., Kirchhefer, U., & Gergs, U. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04214-8 · Cited by 4
White Adipose Tissue in Obesity-Associated HFpEF
Valero‐Muñoz, M., Saw, E. L., Cooper, H. A., Pimentel, D. R., & Sam, F. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.02.021 · Cited by 7
Animal Models of Exercise and Cardiometabolic Disease
Dong, G., RYAN, T. E., & Esser, K. A. (2025) · Circulation Research · doi:10.1161/circresaha.124.325704 · Cited by 6
Radu, D., Parlițeanu, O.-A., Nica, A. E., Voineag, C., Alexe, O., Cristea, A. M., Georgescu, L., Nemeş, R. M., Tiron, A. T., & Nemeş, A. F. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080336 · Cited by 5
“Additionally, this medication has demonstrated benefits in patients with heart failure with preserved ejection fraction, suggesting potential improvements in right ventricular diastolic dysfunction and, as a result, lung volume [29].”
Jabbar, A. B. A., Mansoor, T., Osborne, J., Gilkeson, K., Chinawalkar, A., & Aboeata, A. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05029-4 · Cited by 5
“…(GIP) agonists have potential to reduce to burden of obesity and associated HF and have already demonstrated a significant benefit in HF with preserved ejection fraction (HFpEF) and obesity with clinically meaningful weight loss, improved symptoms, and increased exercise capacity [28, 29].”
Overweight and obesity in metabolic syndrome
Nedogoda, S. V., & Васильевна, Ц. О. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6535 · Cited by 5
Jia, A., Yang, M., Wang, T., Hua, Y., & Lu, H. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1633114 · Cited by 5
Cardiomyopathy in Older Adults
O’Neill, D. E., & Forman, D. E. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02306-8 · Cited by 5
“More recently, glucagon-like peptide-1 receptor agonists (GLP1-RA) have demonstrated benefit in older adults with HFpEF and obesity (BMI of >30), improving weight loss, function and quality of life [27, 28].”
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Self-citationSpall, H. G. C. V., Trullàs, J. C., McGuire, D. K., Zannad, F. M., & McMurray, J. J. V. (2025) · NEJM Evidence · doi:10.1056/evidctw2500258 · Cited by 4
Guo, L., Ding, S., Wang, W., Zhang, H., Dai, S., Li, C., Yuan, Y., Stefański, A., Jouravskaya, I., & FORRESTER, T. D. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103722 · Cited by 5
“33 In patients with diabetes, the SOUL (NCT03914326) and SURPASS-CVOT (NCT04255433) studies have associated semaglutide and tirzepatide, respectively, with cardio-vascular benefits.”
Masuda, T., Kariro, K., & Morishita, Y. (2026) · Hypertension Research · doi:10.1038/s41440-025-02516-1 · Cited by 5
GLP‐1 receptor agonists and reduced dementia risk: Real‐world evidence stacks up
Lam, Y. W., Fajkić, A., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70451 · Cited by 4
Consensus Statement on Optimisation of Patient Care After Hospitalisation for Acute Heart Failure
Sindone, A. P., Amerena, J. V., Pasquale, C. G. D., Chan, A., Gan, G. C. H., RAO, S. D., Burdeniuk, C., Shah, A. M., & Atherton, J. J. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.09.019 · Cited by 4
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“the trial, [106] weekly subcutaneous tirzepatide (up to 15 mg) was compared with placebo over 104 weeks in adults with obesity and heart failure with preserved ejection fraction (HFpEF; LVEF ≥ 50%).”
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
“In the SUMMIT trial [106], weekly subcutaneous tirzepatide (up to 15 mg) was compared with placebo over 104 weeks in adults with obesity and heart failure with preserved ejection fraction (HFpEF; LVEF ≥ 50%).”
Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF
Sauer, A. J., ter Maaten, J. M., & Savarese, G. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag056 · Cited by 5
Sattar, N. A., Lee, C. J., Srinath, R., Schauer, P. R., Wang, H., Falcón, B. L., HE, X., Stefański, A., & Plat, A. W. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101454 · Cited by 6
“Having overweight and obesity increases the risk of all-cause mortality and other health problems, including hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular diseases such as heart failure with preserved ejection fraction [4,5].”
Datta, S., Majumder, S., Gulsin, G. S., Banerjee, A., Primus, C., Mohammed, S., Ricci, F., Aung, N., Sen, G., Gallagher, A. M., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag029 · Cited by 4
Ji, L., Jiang, H., Cheng, Z., Li, X., Pang, S., Zhang, Y., Qiu, W., MA, Q., Liu, Z., Wang, Y., et al. (2026) · Med · doi:10.1016/j.medj.2026.101063 · Cited by 4
GLP-1 medications for weight-loss: a triumph of marketing over patient care
Chastain, R., Meadows, A., & Adams, L. (2026) · Fat Studies · doi:10.1080/21604851.2026.2646492 · Cited by 6
“…et al. 2024; Davies et al. 2021; Garvey et al. 2023; Jastreboff et al. 2022; Kadowaki et al. 2022, 2025; Kosiborod et al. 2023; McGowan et al. 2024; Mu et al. 2024; Packer et al. 2025; Rubino et al. 2021, 2022; Ryan et al. 2024; Wadden et al. 2021, 2023; Wilding et al. 2021; Zhao et al. 2024).”
PCPE-1 promotes cardiac fibrosis with aging and obesity
Hsiao, Y., Yoshida, Y., Tsuchimochi, H., Tang, J., Aung, T. M., Chang, C.-H., Barinda, A. J., Li, Z., Othman, N. S. B., Yoshizaki, T., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.195508 · Cited by 5
“JCI Insight 2026;11(13):e195508 https://doi.org/10.1172/jci.insight.195508”
InfluentialBeyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Bays, H. E., Varney, C., Alexander, L., Ng, J., Tondt, J., Weber, C., Christensen, S. M., Burridge, K., Brown, C., Bindlish, S., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100283 · Cited by 4
“[13,104 – 106 , 111 [13,104 – 106 , 112 ] 9.”
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Dennis, C. J., He, A. Z., Krishnaraj, A., Quan, A., Teoh, H., Connelly, K. A., Hess, D. A., & Verma, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327425 · Cited by 4
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.106951 · Cited by 6
Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF
Nasir, K., & Rochitte, C. E. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.12.013 · Cited by 4
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight lossPreprint
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · medRxiv · doi:10.64898/2026.04.02.26350077 · Cited by 5
Pozzi, A., Spoladore, R., Iorio, A., Corrado, G., & D’Amario, D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10585-0 · Cited by 5
6. Cardio-renal protection in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112150 · Cited by 6
Obesity management: a foundational cardiovascular health priority
Ostrominski, J. W., Plutzky, J., Sattar, N. A., Vaduganathan, M., & Aroda, V. R. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf043 · Cited by 4
Advances in Diagnosis and Treatment of Acute and Chronic Heart Failure: A Comprehensive Review
Kenyon, C. R., Wyk, L. V., Flom, A. P., Ibrahim, R., Pham, H. N., Lakhdar, S., Iftikhar, M., & Abdelnabi, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020618 · Cited by 4
Behers, B. J., Sanchez, C., Hozayen, O., Hozayen, Y., Kammer, R., Corrigan, W. T., Stephenson-Moe, C. A., Miller, M. W., Idriss, M., Cekan, L., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13020103 · Cited by 7
“Six studies met the inclusion criteria and were published from 2019 to 2025 [18–23].”
Use of incretin-based therapies in women using hormone replacement therapy (HRT)
Mukherjee, A., Ghaem-Maghami, S., & Syed, A. A. (2025) · Post Reproductive Health · doi:10.1177/20533691251343069 · Cited by 3
Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
Singh, A. K., Singh, A., & Singh, R. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2464905 · Cited by 5
Cotter, G., Davison, B. A., Biegus, J., Pagnesi, M., Metra, M., Butler, J., Chioncel, O. D., Ponikowski, P. P., & Mebazaa, A. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.12.015 · Cited by 3
Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation
Glaser, K., Glaser, W., Marino, L., Ruchała, M. A., & Bilotta, F. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107510 · Cited by 3
“For instance, one study found that tirzepatide reduced the combined risk of cardiovascular death and worsening heart failure events by 38% compared to placebo in patients with heart failure with preserved ejection fraction and obesity[24].”
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Obstructive Sleep Apnoea Treatments—Where Are We Now?
Luu, S., Lee, D., & Yee, B. J. (2025) · Respirology · doi:10.1111/resp.70109 · Cited by 3
Novel Strategies to Conquer Residual Adiposity Risk in Cardiovascular Disease
Philip, J. S., Shah, A., & Avenatti, E. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01331-w · Cited by 3
“Notably, although Tirzepatide has proven to be effec - tive in improving symptoms associated with HFpEF and OSA [ 34, 35], data is currently lacking on cardiovascular safety in the ASCVD spectrum as the SURMOUNT MMO (CV outcome in patients with obesity) and the SURPASS 1 3 Hounsfield units (HU), CT…”
Reddy, Y. N. V., DeFranco, S., Lerman, A., Demmer, R. T., Chamberlain, A. M., Somers, V. K., & Borlaug, B. A. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.07.009 · Cited by 4
Self-citationFlorescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
“There was no difference in cardiovascular death [33].”
Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review
Wu, Y., Song, M., Chen, X., Chen, W., Wu, M., & Lin, L. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00722-z · Cited by 3
“The SUMMIT trial demonstrated that tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure events by 38% [ 113 ].”
FGF21 Promotes Thermogenesis by Browning Thermogenic Adipose Tissue during Cold Exposure
Li, C.-X., Tan, C.-F., Zhang, Q.-M., Qin, L., Cao, C., & Huang, X.-F. (2025) · Annals of Nutrition and Metabolism · doi:10.1159/000548868 · Cited by 4
“Nevertheless, safe and effective therapies that enhance energy expenditure remain limited [3].”
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
Graham, T., Raghinaru, D., Afreen, S., Ahmann, A., Haidar, A., Raskin, P., Tsoukas, M., Lum, J., Sasson-Katchalski, R., Pinsker, J. E., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1753 · Cited by 3
Management of Ischemic Heart Disease in Patients With Heart Failure
Mielniczuk, L. M., Ahmad, T., Borovac, J. A., Brown, K., Cooper, L. B., Fida, N., Hochman, J. S., Al-Lamee, R. K., Lawton, J. S., Narang, N., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102731 · Cited by 5
Ke, J., Qiu, X., Wang, M., Zeng, H., Wang, C., Zhang, J., Chen, K., & Gu, J. (2025) · Kardiologia Polska · doi:10.33963/v.phj.109920 · Cited by 4
Prieto-Laín, N., Trenas, A., Gómez-Huelgas, R., & Perez-Belmonte, L. M. (2025) · Kardiologia Polska · doi:10.33963/v.phj.110057 · Cited by 3
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3
Alebna, P. L., Martey, S., Mehta, A., Lavie, C. J., & Carbone, S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02333-5 · Cited by 3
“Similarly, the SUMMIT trial, which included 364 patients with HFpEF and obesity, found that treatment with tirzepatide resulted in a 38% reduction in the incidence of the composite outcome of CVD death and HFH events compared to placebo [52].”
Yang, B., 陈奕芝, Xinjie, Z., Li, T., Niu, K., Wang, Z., Xu, X., Huang, Q., Wang, X., Fang, Y., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104022 · Cited by 4
“Recently, there has been increasing attention on the impact of environmental factors on the occurrence and prognosis of MI, with several environmental factors, such as air pollution, extreme temperature events , and endocrine disruptors [18 – 21].”
Irlik, K., Piaśnik, J., Hendel, M., Faron, U., Lip, G. Y. H., Nabrdalik, K., & Prokopidis, K. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag026 · Cited by 3
“26 As these therapies become more widely adopted in clinical practice, future studies may reveal a widening of the outcome differences between HF phenotypes.”
Beyond Blood Pressure: Salt Sensitivity as a Cardiorenal Phenotype—A Narrative Review
Bachlitzanaki, M., Aletras, G., Bachlitzanaki, E., Vasilaki, N., Lydakis, C., Petrakis, I., Foukarakis, E. G., & Stylianou, K. (2026) · Life · doi:10.3390/life16020247 · Cited by 4
“Addressing obesity as a modifiable comorbidity—through structured lifestyle interventions and, when appropriate, pharmacologic strategies—can facilitate BP control, reduce volume burden, and lower long-term cardiovascular risk [105,116,117].”
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
“Treatment with tirzepatide also leads to lower risk of the composite outcome of death from cardiovascular causes and worsening heart failure event: this is largely due to reductions in heart failure events [79].”
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.